Share on
HTML EMBED
Click to Copy
Marketplace Morning Report

Phishing for the greater good

May 22, 2019

Latest Episodes

Share on
HTML EMBED
Click to Copy
Marketplace Morning Report
Share on
HTML EMBED
Click to Copy
Marketplace Morning Report
Share on
HTML EMBED
Click to Copy
Share on
HTML EMBED
Click to Copy
Make Me Smart with Kai and Molly
Share on
HTML EMBED
Click to Copy
Share on
HTML EMBED
Click to Copy
Share on
HTML EMBED
Click to Copy
Marketplace Morning Report
Share on
HTML EMBED
Click to Copy
Marketplace Morning Report
Share on
HTML EMBED
Click to Copy
Marketplace Tech
Share on
HTML EMBED
Click to Copy

FDA approves new Johnson & Johnson drug for depression

Renata Sago Mar 6, 2019
Share Now on:
HTML EMBED:
COPY

The Food and Drug Administration has approved the first new kind of drug to treat depression since Prozac hit the scene in the late 1980s. Spravato is a nasal spray from Johnson & Johnson that’s a close cousin of ketamine, an anesthetic that’s sometimes used recreationally and often known as “Special K.” Because ketamine can cause hallucinations and out-of-body experiences, the new drug must be administered in a clinical setting. The drug is designed to start working in hours instead of weeks. It’s meant to treat people who have not found relief through other antidepressants. That’s about 5 million of the 16 million Americans with depression.

Click the audio player above to hear the full story.

Correction (March 6, 2019): A previous version of this story misspelled Spravato. The text has been corrected.

How We Survive
How We Survive
Climate change is here. Experts say we need to adapt. This series explores the role of technology in helping humanity weather the changes ahead.